SPRO - スマ―トプロス (Spero Therapeutics Inc.)

SPROのニュース

   The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout  2020/06/23 11:57:59 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Affimed NV (NASDAQ: AFMD ) - announced presentation at the AACR Virtual Meeting II, data on the Bristol-Myers Squibb Co (NYSE: BMY ) unit Genentech's RO7297089 and AFM24 developed from Affimed's ROCK platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) (presented at the AACR Virtual Meeting II with pre-clinical data for oncology product candidate) Atossa Therapeutics Inc (NASDAQ: ATOS ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (announced full exercise of over-allotment option in IPO) Cytokinetics, Inc. (NASDAQ: CYTK ) Dyadic International, Inc. (NASDAQ: DYAI ) Evoke Pharma Inc (NASDAQ: EVOK ) ( announced FDA approval for inhaled formulation of its gastroparesis drug) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (moved higher on an analyst upgrade) GENMAB A/S/S ADR (NASDAQ: GMAB ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Halozyme Therapeutics, Inc.
   Earnings Preview: Spero Therapeutics, Inc. (SPRO) Q4 Earnings Expected to Decline  2020/03/05 17:30:40 Zacks Investment Research
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Spero Therapeutics : An amendment to the SC 13G filing | MarketScreener  2020/01/31 22:55:08 MarketScreener
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the… | January 31, 2020
   Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates  2019/08/09 00:30:06 Zacks Investment Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -29.82% and -68.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release  2019/08/01 14:33:06 Zacks Investment Research
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout  2020/06/23 11:57:59 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Affimed NV (NASDAQ: AFMD ) - announced presentation at the AACR Virtual Meeting II, data on the Bristol-Myers Squibb Co (NYSE: BMY ) unit Genentech's RO7297089 and AFM24 developed from Affimed's ROCK platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) (presented at the AACR Virtual Meeting II with pre-clinical data for oncology product candidate) Atossa Therapeutics Inc (NASDAQ: ATOS ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (announced full exercise of over-allotment option in IPO) Cytokinetics, Inc. (NASDAQ: CYTK ) Dyadic International, Inc. (NASDAQ: DYAI ) Evoke Pharma Inc (NASDAQ: EVOK ) ( announced FDA approval for inhaled formulation of its gastroparesis drug) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (moved higher on an analyst upgrade) GENMAB A/S/S ADR (NASDAQ: GMAB ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Halozyme Therapeutics, Inc.
   Earnings Preview: Spero Therapeutics, Inc. (SPRO) Q4 Earnings Expected to Decline  2020/03/05 17:30:40 Zacks Investment Research
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Spero Therapeutics : An amendment to the SC 13G filing | MarketScreener  2020/01/31 22:55:08 MarketScreener
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the… | January 31, 2020
   Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates  2019/08/09 00:30:06 Zacks Investment Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -29.82% and -68.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release  2019/08/01 14:33:06 Zacks Investment Research
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout  2020/06/23 11:57:59 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Affimed NV (NASDAQ: AFMD ) - announced presentation at the AACR Virtual Meeting II, data on the Bristol-Myers Squibb Co (NYSE: BMY ) unit Genentech's RO7297089 and AFM24 developed from Affimed's ROCK platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) (presented at the AACR Virtual Meeting II with pre-clinical data for oncology product candidate) Atossa Therapeutics Inc (NASDAQ: ATOS ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (announced full exercise of over-allotment option in IPO) Cytokinetics, Inc. (NASDAQ: CYTK ) Dyadic International, Inc. (NASDAQ: DYAI ) Evoke Pharma Inc (NASDAQ: EVOK ) ( announced FDA approval for inhaled formulation of its gastroparesis drug) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (moved higher on an analyst upgrade) GENMAB A/S/S ADR (NASDAQ: GMAB ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Halozyme Therapeutics, Inc.
   Earnings Preview: Spero Therapeutics, Inc. (SPRO) Q4 Earnings Expected to Decline  2020/03/05 17:30:40 Zacks Investment Research
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Spero Therapeutics : An amendment to the SC 13G filing | MarketScreener  2020/01/31 22:55:08 MarketScreener
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the… | January 31, 2020
   Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates  2019/08/09 00:30:06 Zacks Investment Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -29.82% and -68.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release  2019/08/01 14:33:06 Zacks Investment Research
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

calendar